1Universidad Francisco Marroquin, School of Medicine, Guatemala City, Guatemala
2Division of Gastroenterology, Hepatology, and Nutrition, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
3Division of Gastroenterology and Hepatology, MD Anderson Cancer Center, Houston, Texas, USA
4Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA
5Division of Gastroenterology and Hepatology, Presbyterian Health Services, Albuquerque, New Mexico, USA
Copyright © 2022 Korean Society of Gastrointestinal Endoscopy
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflicts of Interest
Juan E. Corral: Travel grant from AbbVie, Inc.; Minor food and beverage from Boston Scientific and Cook Medical.
Emmanuel Coronel: Consulting for Boston Scientific.
Michael B. Wallace: Consulting for Virgo Inc, Cosmo/Aries Pharmaceuticals, Anx Robotica (2019), Covidien, and GI Supply; Research grants from Fujifilm, Boston Scientific, Olympus, Medtronic, Ninepoint Medical, Cosmo/ Aries Pharmaceuticals; Stock options from Virgo Inc; Consulting on behalf of Mayo Clinic, GI Supply (2018), Endokey, Endostart, Boston Scientific, and Microtek; General payments/minor food and beverage from Synergy Pharmaceuticals, Boston Scientific, and Cook Medical.
The authors have no potential conflicts of interest.
Funding: None.
Author Contributions
Conceptualization: Juan E. Corral
Data curation: Do Han Kim, Emmanuel Coronel, Paul T. Kröner
Formal analysis: DHK, EC, PTK
Funding acquisition
Investigation: DHK, EC, PTK
Methodology: JEC
Project administration: JEC
Resources: JEC
Supervision: JEC
Validation: Herbert C. Wolfsen, Michael B. Wallace
Visualization: Somashekar G Krishna, MBW
Writing-original draft: JEC
Writing-review & editing: DHK, HCW, MBW
Healthy bile duct | Inflammatory stricture | Malignant stricture | |
---|---|---|---|
Collagen fibrils | Reticular network of thin dark branching bands (<20 μm) | Dark granular pattern in scales Thickened reticular structures | Thick dark bands (>40 μm) |
Background | Light grey | Roughness aspect | Dark clumps |
Vessels | Thin white bands (<20 μm) | Vascular congestion | Thick white bands (>20 μm) |
Epithelium | Enlarged space between scales Increased inter-glandular space | Epithelium visualized (villi, glands) | |
Additional featuresa) | Fluorescein leakage |
Biliary strictures |
|||||||
---|---|---|---|---|---|---|---|
Study | Aim | Study design | Sensitivity | Specificity | Accuracy | Pancreatitis | Comments |
Meining et al. (2011) [24], n=86a) | Diagnosis of cholangiocarcinoma. | Prospective multicenter | 98% | 67% | 81% | 0% | 3 pancreatic strictures included |
Heif et al. (2013) [30], n=15 | Dominant stricture in PSC. | Case series single center | 100% | 61% | 66% | 0% | PSC only |
Caillol et al. (2013) [26], n=60 | Standardize image interpretation | Retrospective image review | 96% | 76% | 85% | NA | Focused on image standardization |
EMID (2015) [31], n=61a) | Malignant vs. benign strictures | Prospective single center | 100% | 71% | 93% | NA | Added EUS-guided biopsies |
FOCUS (2015) [32], n=112 | Malignant vs. benign strictures | Prospective multicenter | 89% | 71% | 82% | 0% | Excluded patients with PSC |
Fugazza et al. (2016) [18], 10 studies, n=494 | Malignant vs. benign strictures | Systematic review and meta-analysis | Pooled 90% | Pooled 72% | Pooled 81% | NA | Also reviewed Barrett’s, gastric and colorectal cancer |
Liu et al. (2016) [17], 8 studies, n=280 | Malignant vs. benign strictures | Systematic review and meta-analysis | Pooled 90% | Pooled 75% | Pooled 82% | NA | |
Dubow et al. (2018) [33], n=97 | Malignant vs. benign strictures | Retrospective single center | 83% | 93% | 90% | NA | Prior ERCP sampling and imaging negative |
Koda et al. (2021) [34], n=7 | Malignant vs. benign strictures | Case series single center | GastroFlexTM 100% | 0% (0/3) | 57.1% | NA | |
CholangioFlexTM 75% | 66.7% | 71.4% | |||||
AlveoFlexTM 75% | 33.3% | 57.1% |
a) In cases of multiple manuscripts published by the same group, we selected the most recent publication or the one with the largest sample.
ERCP, endoscopic retrograde cholangiopancreatography; EUS, endoscopic ultrasonography; NA, not available; nCLE, needle-based confocal laser endomicroscopy; pCLE, probe-based confocal laser endomicroscopy; PSC, primary sclerosing cholangitis.
Pancreatic cysts |
|||||||
---|---|---|---|---|---|---|---|
Study | Aim | Study design | Sensitivity | Specificity | Accuracy | Pancreatitis | Comments |
INSPECT (2013), [35] n=57 | SCA and pseudocyst vs. other cysts | Prospective multicenter | 59% | 100% | 71% | 3% | Early phase defining diagnostic criteria |
DETECT (2015), [36] n=29 | Mucinous vs. other cysts | Prospective single center | 80% | 100% | 89% | 7% | Combination with cystoscopy yields 100% accuracy |
Fugazza et al. (2016), [18] 5 studies, n=163 | Malignancy in pancreatic cysts | Systematic review and meta-analysis | Pooled 68% | Pooled 90% | Pooled 79% | NA | Also reviewed Barrett’s, gastric and colorectal cancer |
CONTACT (2015), [37] n=43 (included 31) | SCA vs. other cysts | Prospective multicenter | SCA 95% | 100% | 99% | 2% | Superior than combination of CEA and cytology analysis |
Indeterminate mucinous 95% | 100% | 97% | |||||
NET 100% | 95% | 96% | |||||
Premalignant cyst 96% | 95% | 96% | |||||
INDEX (2019), [38] n=144 | Mucinous vs. non mucinous pancreatic cysts | Prospective single center | 98% | 94% | 97% | 3% | Superior than combination of CEA and cytology analysis |
CONCYST (2019), [39] n=67 (included 56) | Indeterminate pancreatic cyst | Prospective multicenter | All indeterminate cysts 80% | NA | 77% | 0% | Correlation with pathology and experts was good. Image acquisition took <10 min |
IPMN 90% | 87% | ||||||
Ductal adenocarcinoma 100% | 100% | ||||||
SCA 56% | 38% | ||||||
Pseudocysts 67% | 67% | ||||||
Krishna et al. (2020), [38,40] n=26 | Identify dysplasia in IPMN | INDEX post-hoc analysis | Papillary epithelial width 88% | 100% | 85% | 3% | Allow risk stratification of IPMN |
Papillary epithelial darkness 88% | 100% | 84% | |||||
Hao et al. (2020), [41] n=122 | Solid and cystic pancreatic lesions | Prospective single center | All cysts 94% | 98% | 97% | 5% | |
SCA 89% | 100% | 97% | |||||
MCN 87% | 98% | 94% | |||||
IPMN 97% | 100% | 99% | |||||
Facciorusso et al. (2020), [15] 10 studies, n=536 | Pancreatic cystic lesions | Systematic review and meta-analysis | Pooled 82% | Pooled 97% | 89% | 0% | Mean procedure duration of 6 mins |
Konjeti et al. (2020), [19] 7 studies, n=324 | Pancreatic cystic lesions | Systematic review and meta-analysis | Pooled 85% | 99% | 99% | 1% | High heterogeneity among studies |
Chin et al. (2021), [42] 42 studies, n=519 | Pancreatic cystic lesions | Systematic review | 2.6% | No meta-analysis performed | |||
Pancreatic parenchyma and solid lesions | |||||||
Giovannini et al. (2016), [43] n=40 | Solid pancreatic lesions, compared to pathology | Prospective multicenter. Part of CONTACT | Ductal adenocarcinoma 77% | 100% | 85% | NA | First description of adenocarcinoma, NET and chronic pancreatitis |
Chronic pancreatitis 50% | 100% | 91% | |||||
NET 100% | 97% | 97% | |||||
Hao et al. (2020), [41] n=50 | Solid and cystic pancreatic lesions | Prospective single center | Ductal adenocarcinoma 90% | 89% | 90% | 5% | First description of AIP and tuberculosis |
Healthy bile duct | Inflammatory stricture | Malignant stricture | |
---|---|---|---|
Collagen fibrils | Reticular network of thin dark branching bands (<20 μm) | Dark granular pattern in scales Thickened reticular structures | Thick dark bands (>40 μm) |
Background | Light grey | Roughness aspect | Dark clumps |
Vessels | Thin white bands (<20 μm) | Vascular congestion | Thick white bands (>20 μm) |
Epithelium | Enlarged space between scales Increased inter-glandular space | Epithelium visualized (villi, glands) | |
Additional features |
Fluorescein leakage |
Biliary strictures |
|||||||
---|---|---|---|---|---|---|---|
Study | Aim | Study design | Sensitivity | Specificity | Accuracy | Pancreatitis | Comments |
Meining et al. (2011) [24], n=86 |
Diagnosis of cholangiocarcinoma. | Prospective multicenter | 98% | 67% | 81% | 0% | 3 pancreatic strictures included |
Heif et al. (2013) [30], n=15 | Dominant stricture in PSC. | Case series single center | 100% | 61% | 66% | 0% | PSC only |
Caillol et al. (2013) [26], n=60 | Standardize image interpretation | Retrospective image review | 96% | 76% | 85% | NA | Focused on image standardization |
EMID (2015) [31], n=61 |
Malignant vs. benign strictures | Prospective single center | 100% | 71% | 93% | NA | Added EUS-guided biopsies |
FOCUS (2015) [32], n=112 | Malignant vs. benign strictures | Prospective multicenter | 89% | 71% | 82% | 0% | Excluded patients with PSC |
Fugazza et al. (2016) [18], 10 studies, n=494 | Malignant vs. benign strictures | Systematic review and meta-analysis | Pooled 90% | Pooled 72% | Pooled 81% | NA | Also reviewed Barrett’s, gastric and colorectal cancer |
Liu et al. (2016) [17], 8 studies, n=280 | Malignant vs. benign strictures | Systematic review and meta-analysis | Pooled 90% | Pooled 75% | Pooled 82% | NA | |
Dubow et al. (2018) [33], n=97 | Malignant vs. benign strictures | Retrospective single center | 83% | 93% | 90% | NA | Prior ERCP sampling and imaging negative |
Koda et al. (2021) [34], n=7 | Malignant vs. benign strictures | Case series single center | GastroFlexTM 100% | 0% (0/3) | 57.1% | NA | |
CholangioFlexTM 75% | 66.7% | 71.4% | |||||
AlveoFlexTM 75% | 33.3% | 57.1% |
Pancreatic cysts |
|||||||
---|---|---|---|---|---|---|---|
Study | Aim | Study design | Sensitivity | Specificity | Accuracy | Pancreatitis | Comments |
INSPECT (2013), [35] n=57 | SCA and pseudocyst vs. other cysts | Prospective multicenter | 59% | 100% | 71% | 3% | Early phase defining diagnostic criteria |
DETECT (2015), [36] n=29 | Mucinous vs. other cysts | Prospective single center | 80% | 100% | 89% | 7% | Combination with cystoscopy yields 100% accuracy |
Fugazza et al. (2016), [18] 5 studies, n=163 | Malignancy in pancreatic cysts | Systematic review and meta-analysis | Pooled 68% | Pooled 90% | Pooled 79% | NA | Also reviewed Barrett’s, gastric and colorectal cancer |
CONTACT (2015), [37] n=43 (included 31) | SCA vs. other cysts | Prospective multicenter | SCA 95% | 100% | 99% | 2% | Superior than combination of CEA and cytology analysis |
Indeterminate mucinous 95% | 100% | 97% | |||||
NET 100% | 95% | 96% | |||||
Premalignant cyst 96% | 95% | 96% | |||||
INDEX (2019), [38] n=144 | Mucinous vs. non mucinous pancreatic cysts | Prospective single center | 98% | 94% | 97% | 3% | Superior than combination of CEA and cytology analysis |
CONCYST (2019), [39] n=67 (included 56) | Indeterminate pancreatic cyst | Prospective multicenter | All indeterminate cysts 80% | NA | 77% | 0% | Correlation with pathology and experts was good. Image acquisition took <10 min |
IPMN 90% | 87% | ||||||
Ductal adenocarcinoma 100% | 100% | ||||||
SCA 56% | 38% | ||||||
Pseudocysts 67% | 67% | ||||||
Krishna et al. (2020), [38,40] n=26 | Identify dysplasia in IPMN | INDEX post-hoc analysis | Papillary epithelial width 88% | 100% | 85% | 3% | Allow risk stratification of IPMN |
Papillary epithelial darkness 88% | 100% | 84% | |||||
Hao et al. (2020), [41] n=122 | Solid and cystic pancreatic lesions | Prospective single center | All cysts 94% | 98% | 97% | 5% | |
SCA 89% | 100% | 97% | |||||
MCN 87% | 98% | 94% | |||||
IPMN 97% | 100% | 99% | |||||
Facciorusso et al. (2020), [15] 10 studies, n=536 | Pancreatic cystic lesions | Systematic review and meta-analysis | Pooled 82% | Pooled 97% | 89% | 0% | Mean procedure duration of 6 mins |
Konjeti et al. (2020), [19] 7 studies, n=324 | Pancreatic cystic lesions | Systematic review and meta-analysis | Pooled 85% | 99% | 99% | 1% | High heterogeneity among studies |
Chin et al. (2021), [42] 42 studies, n=519 | Pancreatic cystic lesions | Systematic review | 2.6% | No meta-analysis performed | |||
Pancreatic parenchyma and solid lesions | |||||||
Giovannini et al. (2016), [43] n=40 | Solid pancreatic lesions, compared to pathology | Prospective multicenter. Part of CONTACT | Ductal adenocarcinoma 77% | 100% | 85% | NA | First description of adenocarcinoma, NET and chronic pancreatitis |
Chronic pancreatitis 50% | 100% | 91% | |||||
NET 100% | 97% | 97% | |||||
Hao et al. (2020), [41] n=50 | Solid and cystic pancreatic lesions | Prospective single center | Ductal adenocarcinoma 90% | 89% | 90% | 5% | First description of AIP and tuberculosis |
Epithelial patterns | Vascular patterns | |||
---|---|---|---|---|
Papillae or epithelial bands | Dark background with bright particles | Trabecular pattern | Branched or rope-ladder pattern | Fern pattern (in the absence of any epithelial features) |
IPMN, MCN | Pseudocyst | Cystic-NET, SPT | IPMN, MCN | SCA |
Accuracy 96% | Accuracy 98% | Accuracy 97% | Accuracy 75% | Accuracy 99% |
Papillae: IPMN | Epithelial bands, chronic inflammation: MCN | |||
High-grade dysplasia: Papillary width ≥50 μm | ||||
Papillary darkness ≤90 pixel intensity |
Findings | |
---|---|
Adenocarcinoma | Dark cell aggregates |
Irregular vessels with fluorescein leakage | |
Chronic and autoimmune pancreatitis | Residual regular glandular pancreatic structures |
Massive fibrous areas | |
Neuroendocrine tumor | Black cell aggregates surrounded by vessels and fibrotic areas |
Solid pseudopapillary tumor | Black columnar protrusions near the vascular area |
Tuberculosis | Black huge cells (may correspond to macrophages) mixing with vesicular adipocytes |
Suggested in the Miami classification but not included in the Paris classification [
In cases of multiple manuscripts published by the same group, we selected the most recent publication or the one with the largest sample. ERCP, endoscopic retrograde cholangiopancreatography; EUS, endoscopic ultrasonography; NA, not available; nCLE, needle-based confocal laser endomicroscopy; pCLE, probe-based confocal laser endomicroscopy; PSC, primary sclerosing cholangitis.
AIP, autoimmune pancreatitis; CEA, carcinoembryonic antigen; IPMN, intraductal papillary mucinous neoplasm; NA, not available; nCLE, needle-based confocal laser endomicroscopy; NET, neuroendocrine tumor; pCLE, probe-based confocal laser endomicroscopy; SCA, serous cystadenoma.
IPMN, intraductal mucinous papillary neoplasm; MCN, mucinous cystic neoplasm; Ncle, needle-based confocal laser endomicroscopy; NET, neuroendocrine tumor; SCA, serous cystadenoma; SPT, solid pseudopapillary tumor.